Publicaciones año 2016

AÑOS DE PUBLICACIÓN:

2019 || 2018 || 2017 || 2016 || 2015 ||  2014  ||  2013  ||  2012  ||  2011  ||  2010  ||  2009  ||  2008  ||  2007  |

2016

Can the CEIBA Cocktail designed for human cytochrome P450 enzymes be used in the rat for drug interaction studies?.
Magalhães P, De Andrés F, Falcão A, LLerena A, Alves G.
J Pharm Pharm Sci. 2016 Oct – Dec;19(4):520-529.


To genotype or phenotype for personalized medicine? CYP450 drug metabolizing enzyme genotype-phenotype concordance and discordance in the Ecuadorian population. 
De Andrés F, Terán S, Hernández F, Terán E, LLerena A.
OMICS. 2016 Dec;20(12):699-710.


Genetic variability of CYP2C9*2 and CYP2C9*3 in seven indigenous groups from Mexico.
Sánchez-Pozos K, Rivera-Santiago C, García-Rodríguez MH, Ortiz-López MG, Peña-Espinoza BI, Granados-Silvestre ML, Llerena A, Menjívar M.
Pharmacogenomics. 2016 Nov;17(17):1881-1889


Pharmacogenetics and ethnicity: relevance for clinical implementation, clinical trials, pharmacovigilance and drug regulation in Latin America.
Sosa-Macías M, Teran E, Waters W, Fors MM, Altamirano C, Jung-Cook H, Galaviz-Hernández C, López-López M, Remírez D, Moya GE, Hernández F, Fariñas H,Ramírez R, Céspedes-Garro C, Tarazona-Santos E, LLerena A.
Pharmacogenomics. 2016 Nov;17(16):1741-1747.


Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-mestizo healthy volunteers.
Fricke-Galindo I, Ortega-Vázquez A, Monroy-Jaramillo N, Dorado P, Jung-Cook H, Peñas-Lledó E, LLerena A, López-López M.
Pharmacogenomics. 2016 Nov;17(17):1913-1930.


Simultaneous determination of cytochrome P450 oxidation capacity in humans: A review on the phenotyping cocktail approach.
de Andrés F, LLerena A.
Curr Pharm Biotechnol. 2016;17(13):1159-1180.


Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.
Céspedes-Garro C, Naranjo MG, Rodrigues-Soares F, LLerena A, Duconge J, Montané-Jaime LK, Roblejo H, Fariñas H, Campos ML, Ramírez R, Serrano V, Villagrán CI, Peñas-LLedó EM.
Pharmacogenomics. 2016 Oct;17(15):1707-1724.


Relevance of the ancestry for the variability of the Drug-Metabolizing Enzymes CYP2C9, CYP2C19and CYP2D6 polymorphisms in a multiethnic Costa Rican population.
Céspedes-Garro C, Rodrigues-Soares F, Jiménez-Arce G, Naranjo MG, Tarazona-Santos E, Fariñas H, Barrantes R, Llerena A; CEIBA. FP Consortium of the Ibero-American Network of Pharmacogenetics & Pharmacogenomics RIBEF.
Rev Biol Trop. 2016 Sep;64(3):1067-76.


High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies.
Naranjo ME, de Andrés F, Delgado A, Cobaleda J, Peñas-Lledó EM, Llerena A.
Pharmacogenomics J. 2016 Oct;16(5):485-90.


High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina.
Moya G, Dorado P, Ferreiro V, Naranjo MEG, Peñas-Lledó EM, LLerena A.
Pharmacogenomics J. 2017 Jul;17(4):378-381.


Predictive biomarkers candidates for patients with metastatic colorectal cancer treated with bevacizumab-containing regimen.
González-Vacarezza N, Alonso I, Arroyo G, Martínez J, De Andrés F, LLerena A, Estévez-Carrizo F.
Drug Metab Pers Ther. 2016 Jun 1;31(2):83-90.


Interethnic variability of pharmacogenetic biomarkers in Mexican healthy volunteers: a report from the RIBEF (Ibero-American Network of Pharmacogenetics and Pharmacogenomics).
Fricke-Galindo I, Jung-Cook H, LLerena A, López-López M.
Drug Metab Pers Ther. 2016 Jun 1;31(2):61-81.

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies

ACEPTAR
Aviso de cookies